Patterns and risk factors for locoregional failures after mastectomy for breast cancer: An International Breast Cancer Study Group Report

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2852-2858

  Karlsson, P ^a   Cole, B F ^b,c   Chua, B H ^d   Price, K N ^c,e   Lindtner, J ^f   Collins, J P ^g   Kovacs A ^a   Thurlimann B ^h,p   Crivellari, D ⁱ   Castiglione Gertsch, M ^j   Forbes, J F ^k   Gelber, R D ^c,e,l   Goldhirsch, A ^m,n   Gruber, G ^o  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Vermont ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h The Breast Center   (Sweden)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j University Hospital   (Switzerland)

^k UNIVERSITY OF NEWCASTLE   (Australia)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ Sant'Anna Clinics   (Sweden)

^o Klinik Hirslanden   (Sweden)

^p Switzerland and Swiss Group for Clinical Cancer Research (SAKK)   (Sweden)

more..

Author keywords

Adjuvant treatment; Breast cancer; Locoregional recurrence; Postmastectomy radiotherapy

Indexed keywords

EID: 84868095433     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds118     Document Type: Article

References (44)

1. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
2. Taghian A, Jeong JH, Mamounas E et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004; 22: 4247-4254.
3. Kyndi M, Sorensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-1426.
4. Kyndi M, Overgaard M, Nielsen HM et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in highrisk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 2009; 90: 74-79.
5. Ceilley E, Jagsi R, Goldberg S et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005; 61: 365-373.
6. Wallgren A, Bonetti M, Gelber RD et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003; 21: 1205-1213.
7. Karlsson P, Cole BF, Price KN et al. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 2007; 25: 2019-2026.
8. Castiglione-Gertsch M, Johnsen C, Goldhirsch A et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994; 5: 717-724.
9. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for nodepositive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677-683.
10. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491-496.
11. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-1894.
12. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-1394.
13. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
14. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
15. Thurlimann B, Price KN, Gelber RD et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113: 137-144.
16. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004; 15: 1749-1759.
17. International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol 2007; 18: 1177-1184.
18. Davis BW, Gelber RD, Goldhirsch A et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 1985; 16: 1212-1218.
19. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley 1980.
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
22. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York: Wiley 1991.
23. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: Subpopulation Treatment Effect Pattern Plot. J Clin Oncol 2010; 28: 4539-4544.
24. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in highrisk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955.
25. Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy in highrisk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-1648.
26. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962.
27. Pierce S, Recht A, Lingos T et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23: 915-923.
28. Lingos T, Recht A, Vicini F et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21: 355-360.
29. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
30. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-up. Ann Oncol 2010; 21Suppl 5v9-v14.
31. Strom E, Woodward WA, Katz A et al. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 1508-1513.
32. Gruber G, Cole BF, Castiglione-Gertsch M et al. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008; 19: 1393-1401.
33. Darby S. Overview of randomised trials of radiotherapy in early breast cancer. Cancer Res 2009; 69 (Suppl 24) (Abstr MS3-1).
34. Macdonald SM, Abi-Raad RF, Alm El-Din MA et al. Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 2009; 75: 1297-1303.
35. Vicini FA, Horwitz EM, Lacerna MD et al. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breastconserving therapy. Int J Radiat Oncol Biol Phys 1997; 39: 1069-1076.
36. Recht A, Pierce SM, Abner A et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991; 9: 988-996.
37. Recht A, Gray R, Davidson NE et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 1689-1700.
38. Livi L, Scotti V, Saieva C et al. Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation. Int J Radiat Oncol Biol Phys 2010; 76: 978-983.
39. Truong PT, Jones SO, Kader HA et al. Patients with T1 to T2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 357-364.
40. Yu JI, Park W, Huh SJ et al. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer. Int J Radiat Oncol Biol Phys 2010; 78: 1135-1141.
41. Whelan TJ, Olivotto I, Ackerman I et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011; 29 (18 suppl) LBA1003.
42. Vinh-Hung V, Cserni G, Burzykowski T et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep 2003; 10: 363-368.
43. Salama JK, Heimann R, Lin F et al. Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?. Cancer 2005; 103: 664-671.
44. Truong PT, Woodward WA, Thames HD et al. The ratio of ositive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007; 68: 59-65.